The research endeavors to examine the critical composition of Polyunsaturated Fatty Acids (PUFAs) in premature infants across different gestational stages and under varying disease conditions, and delineate the metabolic attributes of PUFAs in premature infants and their interplay with the onset of diseases. This study anticipates furnishing a theoretical foundation for the rationalization of PUFAs supplementation in premature infants and for informing strategies related to disease prevention and management.
None
None
Neonates born within 24 hours who were admitted to the Neonatology Department of the First Hospital of Jilin University, including premature infants born between 24 and 36 weeks of gestational age and full-term infants from September 2023 to August 2026, n
Cohort
Prospective
Not listed
Mortality and severe complications of premature infants
incidence of death，NEC，PDA，BPD，IVH，PVL and sepsis
Mortality
death
NEC
Bell stage II or III
PDA
confirmed by echocardiography
BPD
nasal CPAP/NIPPV or invasive ventilation requirement at 36 weeks postmenstrual age or at discharge, transfer or death if before 36 weeks
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
